Purchase this article with an account.
J. D. Holweger, E. D. Roth, I. Ahmad, D. M. Chacko; Combination Therapy Using Verteporfin (PDT) and Pegaptanib Injections for Treatment of Exudative AMD. Invest. Ophthalmol. Vis. Sci. 2007;48(13):3363.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To examine the effectiveness of a combination therapy of intravitreal pegaptanib injections and verteporfin photodynamic therapy (PDT-V) in treating exudative age-related macular degeneration.
Retrospective review of 48 eyes of 47 patients with all types of exudative macular degeneration (average lesion size of 3012 microms) treated with a combination of PDT-V and .03mg pegaptanib injections. Most patients were treated every 3 to 4 weeks by alternating PDT-V with injections. The average treatment duration and follow up was 16 months with a median of 12 months.
Sixteen eyes (33%) gained an average of 24.8 letters while 27 eyes (56.3%) lost an average of 36.3 letters. The average pre-treatment vision was 20/160-2 (range: HM to 20/20) while the average post-treatment visual acuity was 20/300 (range: CF to 20/30). Twenty-eight eyes (58%) lost less than 15 letters of visual acuity. At their last checkup, 26 eyes had a visual acuity of 20/100 or better.
Combination therapy may be more effective than monotherapy in improving vision. It is very effective in reducing leakage and maintaining visual acuity >20/100.
This PDF is available to Subscribers Only